Prognosis Estimation Under the Light of Metabolic Tumor Parameters on Initial Fdg-Pet/Ct in Patients with Primary Extranodal Lymphoma
Tarih
2016Yazar
Okuyucu, Kursat
Ozaydın, Sukru
Alagoz, Engin
Ozgur, Gokhan
Ince, Semra
Oysul, Fahrettin Guven
Ozmen, Ozlem
Tuncel, Murat
Ozturk, Mustafa
Arslan, Nuri
Üst veri
Tüm öğe kaydını gösterÖzet
Background Non-Hodgkin’s lymphomas arising from the tissues other than primary lymphatic organs are named primary extranodal lymphoma. Most of the studies evaluated metabolic tumor parameters in different organs and histopathologic variants of this disease generally for treatment response. We aimed to evaluate the prognostic value of metabolic tumor parameters derived from initial FDG-PET/CT in patients with a medley of primary extranodal lymphoma in this study. Patients and methods There were 67 patients with primary extranodal lymphoma for whom FDG-PET/CT was requested for primary staging. Quantitative PET/CT parameters: maximum standardized uptake value (SUVmax), average standardized uptake value (SUVmean), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were used to estimate disease-free survival and overall survival. Results SUVmean, MTV and TLG were found statistically significant after multivariate analysis. SUVmean remained significant after ROC curve analysis. Sensitivity and specificity were calculated as 88% and 64%, respectively, when the cut-off value of SUVmean was chosen as 5.15. After the investigation of primary presentation sites and histo-pathological variants according to recurrence, there is no difference amongst the variants. Primary site of extranodal lymphomas however, is statistically important (p = 0.014). Testis and central nervous system lymphomas have higher recurrence rate (62.5%, 73%, respectively). Conclusions High SUVmean, MTV and TLG values obtained from primary staging FDG-PET/CT are potential risk factors for both disease-free survival and overall survival in primary extranodal lymphoma. SUVmean is the most significant one amongst them for estimating recurrence/metastasis.
Bağlantı
https://doi.org/10.1515/raon-2016-0045https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120580/
http://hdl.handle.net/11655/15782